Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis. Issue 164 (April 2018)

• Record Type: Journal Article
• Authors: Tufano, Antonella; Ageno, Walter; Di Micco, Pierpaolo; Niglio, Alferio; Rosa, Vladimir; Ballaz, Aitor; Braester, Andrei; Rubio, Carmen Mª.; Isern, Virginia; Imbalzano, Egidio; Monreal, Manuel
• Is Part Of: Thrombosis research. Issue 164(2018)
• Page Start: 69
• Page End: 74
• Publication Date: 2018-04
• Subjects: SVT splanchnic vein thrombosis -- VTE venous thromboembolism -- DVT deep vein thrombosis -- PE pulmonary embolism; Splanchnic vein thrombosis -- Recurrences -- Bleeding -- Anticoagulant therapy; Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/j.thromres.2018.02.143
• Languages: English
• ISSNs: 0049-3848

Abstract

Abstract: Introduction: Current guidelines recommend the use of anticoagulant therapy in patients with symptomatic splanchnic vein thrombosis (SVT) and suggest no routine anticoagulation in those with incidental SVT. Methods: We used the RIETE (Registro Informatizado Enfermedad Trombo Embólica) registry to assess the rate and severity of symptomatic venous thromboembolism (VTE) recurrences and major bleeding events appearing during the course of anticoagulation in patients with symptomatic or incidental SVT. Results: In March 2017, 521 patients with SVT were recruited. Of them, 212 (41%) presented with symptomatic SVT and 309 had incidental SVT. Most (93%) patients received anticoagulant therapy (median, 147 days). During the course of anticoagulation, 20 patients developed symptomatic VTE recurrences (none died) and 26 had major bleeding (fatal bleeding, 5). On multivariable analysis, patients with incidental SVT had a non-significantly higher risk for symptomatic VTE recurrences (adjusted hazard ratio [HR]: 2.04; 95%CI: 0.71–5.88) and a similar risk for major bleeding (HR: 1.12; 95%CI: 0.47–2.63) than those with symptomatic SVT. Active cancer was associated with at increased risk for VTE recurrences (HR: 3.06; 95%CI: 1.14–8.17) and anaemia (HR: 4.11; 95%CI: 1.45–11.6) or abnormal prothrombin time (HR: 4.10; 95%CI: 1.68–10.1) were associated with at increased risk for major bleeding. Conclusions: The rates of recurrent SVT and major bleeding were similar between patients with incidental or symptomatic SVT. Because the severity of bleeding complications during anticoagulation may outweigh the severity of VTE recurrences in both groups, further studies should identify those SVT patients who benefit from anticoagulant therapy. Highlights: Current guidelines recommend to anticoagulate SVT only if symptomatic. We assessed the rate and severity of VTE recurrences and major bleeding during therapy. During anticoagulation, the severity of bleeding may outweigh the severity of recurrences. Further studies should identify what SVT patients may benefit from anticoagulation.